CU20170052A7 - Moléculas de anticuerpo que se unen a pd-l1 - Google Patents
Moléculas de anticuerpo que se unen a pd-l1Info
- Publication number
- CU20170052A7 CU20170052A7 CUP2017000052A CU20170052A CU20170052A7 CU 20170052 A7 CU20170052 A7 CU 20170052A7 CU P2017000052 A CUP2017000052 A CU P2017000052A CU 20170052 A CU20170052 A CU 20170052A CU 20170052 A7 CU20170052 A7 CU 20170052A7
- Authority
- CU
- Cuba
- Prior art keywords
- antibody molecules
- join
- disorders
- treat
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Radiology & Medical Imaging (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
Abstract
<p>La presente invención se relaciona con moléculas de anticuerpo que se unen específicamente a PD-L1. También se divulgan terapias de combinación que comprenden moléculas de anticuerpo anti-PD-L 1. Las moléculas de anticuerpo anti-PD-L 1 se pueden usar para tratar, prevenir y/o diagnosticar afecciones y trastornos cancerosos o infecciosos.</p>
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462063852P | 2014-10-14 | 2014-10-14 | |
US201462094847P | 2014-12-19 | 2014-12-19 | |
US201562198545P | 2015-07-29 | 2015-07-29 | |
US201562213076P | 2015-09-01 | 2015-09-01 | |
PCT/US2015/055390 WO2016061142A1 (en) | 2014-10-14 | 2015-10-13 | Antibody molecules to pd-l1 and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CU20170052A7 true CU20170052A7 (es) | 2017-11-07 |
Family
ID=54347916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CUP2017000052A CU20170052A7 (es) | 2014-10-14 | 2015-10-13 | Moléculas de anticuerpo que se unen a pd-l1 |
Country Status (26)
Country | Link |
---|---|
US (3) | US9988452B2 (es) |
EP (2) | EP4245376A3 (es) |
JP (3) | JP6877339B2 (es) |
KR (1) | KR102513870B1 (es) |
CN (2) | CN107001478B (es) |
AU (1) | AU2015333687B2 (es) |
BR (1) | BR112017007379A2 (es) |
CA (1) | CA2964367C (es) |
CL (1) | CL2017000888A1 (es) |
CO (1) | CO2017003490A2 (es) |
CR (1) | CR20170143A (es) |
CU (1) | CU20170052A7 (es) |
EA (1) | EA201790834A1 (es) |
EC (1) | ECSP17029218A (es) |
ES (1) | ES2952717T3 (es) |
GT (1) | GT201700081A (es) |
IL (1) | IL251563B (es) |
MA (1) | MA40035A (es) |
MX (1) | MX2017004810A (es) |
PE (1) | PE20171067A1 (es) |
PH (1) | PH12017500692A1 (es) |
SG (1) | SG11201702401RA (es) |
TN (1) | TN2017000129A1 (es) |
TW (1) | TWI716362B (es) |
UY (1) | UY36351A (es) |
WO (1) | WO2016061142A1 (es) |
Families Citing this family (336)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2350075B1 (en) | 2008-09-22 | 2014-03-05 | Array Biopharma, Inc. | Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors |
HUE057625T2 (hu) | 2008-10-22 | 2022-05-28 | Array Biopharma Inc | TRK kináz inhibitor szubsztituált pirazolo[1,5-a]pirimidin vegyületek |
UA109108C2 (uk) | 2008-12-09 | 2015-07-27 | Дженентек, Інк. | Антитіло до pd-l1 та його застосування для посилення функції t-клітин |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
WO2011146336A1 (en) | 2010-05-20 | 2011-11-24 | Array Biopharma Inc. | Macrocyclic compounds as trk kinase inhibitors |
CN103153311A (zh) | 2010-06-03 | 2013-06-12 | 药品循环公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的应用 |
CN103517990A (zh) | 2010-10-07 | 2014-01-15 | 通用医疗公司 | 癌症生物标志物 |
WO2012149540A1 (en) | 2011-04-28 | 2012-11-01 | The Broad Institute Inc | Inhibitors of histone deacetylase |
WO2013013188A1 (en) | 2011-07-21 | 2013-01-24 | Tolero Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors |
EP2877598A1 (en) | 2012-07-24 | 2015-06-03 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
CA2880117C (en) | 2012-07-27 | 2021-04-06 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
US10034939B2 (en) * | 2012-10-26 | 2018-07-31 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
CN105939699B (zh) | 2013-12-03 | 2020-10-02 | 西北大学 | 脂质体颗粒、制备所述脂质体颗粒的方法以及其用途 |
CN106102774A (zh) * | 2013-12-17 | 2016-11-09 | 豪夫迈·罗氏有限公司 | 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法 |
TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
CA2974651A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
CA3210360A1 (en) | 2014-02-04 | 2015-08-13 | Pfizer Inc. | Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer |
US11369690B2 (en) * | 2014-03-03 | 2022-06-28 | Academia Sinica & Kaohsiung Medical University | Bi-specific antibodies and uses thereof |
JP6447887B2 (ja) * | 2014-03-03 | 2019-01-09 | アカデミア シニカAcademia Sinica | 二重特異性抗体及びその使用 |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
CU24481B1 (es) | 2014-03-14 | 2020-03-04 | Immutep Sas | Moléculas de anticuerpo que se unen a lag-3 |
MX2016012779A (es) | 2014-03-31 | 2017-04-27 | Genentech Inc | Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40. |
EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
US9993551B2 (en) | 2014-09-13 | 2018-06-12 | Novartis Ag | Combination therapies of EGFR inhibitors |
TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對pd-l1之抗體分子及其用途 |
EP3215852A4 (en) | 2014-11-05 | 2018-04-04 | The Regents of the University of California | Methods for stratifying non-responders to therapies that block pd1/pdl1 axis |
US20160129108A1 (en) * | 2014-11-11 | 2016-05-12 | Medimmune Limited | Therapeutic combinations comprising anti-cd73 antibodies and uses thereof |
TWI746426B (zh) | 2014-11-16 | 2021-11-21 | 美商亞雷生物製藥股份有限公司 | (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
CN107405401B (zh) * | 2015-02-26 | 2022-02-01 | 默克专利股份公司 | 用于治疗癌症的pd-1/pd-l1抑制剂 |
MX2017011644A (es) | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. |
BR112017020002A2 (pt) * | 2015-03-20 | 2018-06-19 | Syndax Pharmaceuticals Inc | Combinação de inibidor de hdac e anticorpo anti- pd-1 para o tratamento de câncer |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
EP3280439A1 (en) * | 2015-04-07 | 2018-02-14 | INSERM - Institut National de la Santé et de la Recherche Médicale | Anti-pd-l1 immunotoxin for use in therapy |
SG10202008304TA (en) | 2015-05-29 | 2020-10-29 | Bristol Myers Squibb Co | Antibodies against ox40 and uses thereof |
SI3303394T1 (sl) | 2015-05-29 | 2020-10-30 | Agenus Inc. | Protitelesa proti-CTLA-4 in postopki njihove uporabe |
EP3310810A1 (en) | 2015-06-16 | 2018-04-25 | Merck Patent GmbH | Pd-l1 antagonist combination treatments |
NZ739503A (en) | 2015-07-16 | 2023-06-30 | Bioxcel Therapeutics Inc | A novel approach for treatment of cancer using immunomodulation |
TW201708538A (zh) | 2015-07-21 | 2017-03-01 | 諾華公司 | 改良免疫細胞之功效及擴展之方法 |
US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
PT3317301T (pt) | 2015-07-29 | 2021-07-09 | Novartis Ag | Terapias de associação compreendendo moléculas de anticorpo contra lag-3 |
KR102434314B1 (ko) | 2015-09-01 | 2022-08-19 | 아게누스 인코포레이티드 | 항-pd-1 항체 및 이를 이용하는 방법 |
US11747346B2 (en) | 2015-09-03 | 2023-09-05 | Novartis Ag | Biomarkers predictive of cytokine release syndrome |
UA125962C2 (uk) | 2015-10-02 | 2022-07-20 | Ф. Хоффманн-Ля Рош Аг | Біспецифічна антигензв'язуюча молекула до ox40 та фібробласт-активуючого білка (fap) |
RU2744852C2 (ru) | 2015-10-26 | 2021-03-16 | Локсо Онколоджи, Инк. | Точечные мутации в устойчивых к ингибитору trk злокачественных опухолях и связанные с ними способы |
WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
JP2019503349A (ja) | 2015-12-17 | 2019-02-07 | ノバルティス アーゲー | Pd−1に対する抗体分子およびその使用 |
DK3402515T3 (da) | 2016-01-12 | 2021-11-15 | Oncotracker Inc | Forbedrede fremgangsmåder til monitorering af et individs immunstatus |
WO2017134306A1 (en) | 2016-02-05 | 2017-08-10 | Orionis Biosciences Nv | Cd8 binding agents |
KR20220147693A (ko) * | 2016-02-15 | 2022-11-03 | 에프케이디 테라피즈 리미티드, | 향상된 인터페론 치료 |
HUE058114T2 (hu) * | 2016-02-15 | 2022-07-28 | Astrazeneca Ab | Cediranib rögzített idõszakos adagolását tartalmazó eljárások |
US11497781B2 (en) * | 2016-03-10 | 2022-11-15 | Cg Oncology, Inc. | Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor |
WO2017176751A1 (en) | 2016-04-04 | 2017-10-12 | Loxo Oncology, Inc. | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
WO2017189976A1 (en) * | 2016-04-29 | 2017-11-02 | Board Of Regents, The University Of Texas System | Targeted measure of transcriptional activity related to hormone receptors |
AR108377A1 (es) | 2016-05-06 | 2018-08-15 | Medimmune Llc | Proteínas de unión biespecíficas y sus usos |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
TWI755395B (zh) | 2016-05-13 | 2022-02-21 | 美商再生元醫藥公司 | 抗-pd-1抗體與輻射治療癌症之組合 |
EP3455245A2 (en) | 2016-05-13 | 2019-03-20 | Orionis Biosciences NV | Therapeutic targeting of non-cellular structures |
WO2017194783A1 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Targeted mutant interferon-beta and uses thereof |
WO2017201165A1 (en) * | 2016-05-17 | 2017-11-23 | Genecentric Diagnostics, Inc. | Methods for subtyping of lung adenocarcinoma |
CN109863251B (zh) * | 2016-05-17 | 2022-11-18 | 基因中心治疗公司 | 对肺鳞状细胞癌亚型分型的方法 |
DK3458478T3 (da) | 2016-05-18 | 2021-03-22 | Boehringer Ingelheim Int | Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling |
JP7443057B2 (ja) | 2016-05-18 | 2024-03-05 | ロクソ オンコロジー, インコーポレイテッド | (S)-N-(5-((R)-2-(2,5-ジフルオロフェニル)ピロリジン-1-イル)-ピラゾロ[1,5-a]ピリミジン-3-イル)-3-ヒドロキシピロリジン-1-カルボキサミドの調製 |
CN105968200B (zh) * | 2016-05-20 | 2019-03-15 | 瑞阳(苏州)生物科技有限公司 | 抗人pd-l1人源化单克隆抗体及其应用 |
CN106008714B (zh) | 2016-05-24 | 2019-03-15 | 瑞阳(苏州)生物科技有限公司 | 抗人pd-1人源化单克隆抗体及其应用 |
CN116041514A (zh) | 2016-06-06 | 2023-05-02 | 希望之城 | Baff-r抗体及其用途 |
CA3027209C (en) | 2016-06-13 | 2022-08-16 | I-Mab | Anti-pd-l1 antibodies and uses thereof |
CN109475603B (zh) | 2016-06-20 | 2023-06-13 | 科马布有限公司 | 抗pd-l1抗体 |
WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
TW201803598A (zh) | 2016-06-30 | 2018-02-01 | 南特細胞公司 | Nant癌症疫苗 |
EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
CN115317603A (zh) | 2016-07-07 | 2022-11-11 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
US20190269666A1 (en) * | 2016-07-29 | 2019-09-05 | Eli Lilly And Company | Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer |
US11046776B2 (en) | 2016-08-05 | 2021-06-29 | Genentech, Inc. | Multivalent and multiepitopic antibodies having agonistic activity and methods of use |
AU2017306507B2 (en) * | 2016-08-05 | 2020-05-14 | Y-Biologics Inc. | Antibody to programmed death-ligand 1 (PD-L1) and use thereof |
WO2018026249A1 (ko) * | 2016-08-05 | 2018-02-08 | 주식회사 와이바이오로직스 | 프로그램화된 세포 사멸 단백질 리간드-1 (pd-l1)에 대한 항체 및 이의 용도 |
JP7198752B2 (ja) | 2016-08-09 | 2023-01-04 | カイマブ・リミテッド | 抗icos抗体 |
CA3032542A1 (en) * | 2016-08-12 | 2018-02-15 | Genentech, Inc. | Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor |
AU2017312121A1 (en) * | 2016-08-19 | 2019-03-21 | Brooklyn Immunotherapeutics Llc | Uses of PD-1/PD-L1 inhibitors and/or CTLA-4 inhibitors with a biologic containing multiple cytokine components to treat cancer |
WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
JP2019535001A (ja) * | 2016-09-06 | 2019-12-05 | インセルディーエックス・インコーポレーテッド | 細胞あたりのpd−l1発現量を検出する方法及びその使用 |
US11726089B2 (en) | 2016-09-06 | 2023-08-15 | Incelldx, Inc. | Methods of assaying neoplastic and neoplasia-related cells and uses thereof |
CA3036564A1 (en) * | 2016-09-23 | 2018-03-29 | Elstar Therapeutics, Inc. | Multispecific antibody molecules comprising lambda and kappa light chains |
EP3522923A1 (en) | 2016-10-06 | 2019-08-14 | Pfizer Inc | Dosing regimen of avelumab for the treatment of cancer |
TWI764943B (zh) * | 2016-10-10 | 2022-05-21 | 大陸商蘇州盛迪亞生物醫藥有限公司 | 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途 |
WO2018068201A1 (en) * | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
CA3040802A1 (en) | 2016-10-24 | 2018-05-03 | Orionis Biosciences Nv | Targeted mutant interferon-gamma and uses thereof |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
US20190275092A1 (en) * | 2016-11-01 | 2019-09-12 | Dnatrix, Inc. | Combination therapy for treatment of brain cancers |
EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
WO2018089688A1 (en) | 2016-11-09 | 2018-05-17 | Jinjun Shi | Restoration of tumor suppression using mrna-based delivery system |
WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
WO2018098352A2 (en) * | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
JP2019505516A (ja) * | 2016-11-28 | 2019-02-28 | ノバルティス アーゲー | インターロイキン−17(il−17)アンタゴニストを使用してざ瘡を治療する方法 |
HRP20231579T1 (hr) | 2016-12-07 | 2024-03-15 | Agenus Inc. | Anti-ctla-4 antitijela i postupci njihove upotrebe |
WO2018107244A1 (en) | 2016-12-15 | 2018-06-21 | Progen Pg500 Series Pty Ltd | Composition and uses thereof |
US20230242876A1 (en) * | 2016-12-30 | 2023-08-03 | Shanghai Sinobio Biotech Co., Ltd. | Bifunctional molecule and use thereof |
RU2019124875A (ru) * | 2017-01-07 | 2021-02-08 | Мерк Патент Гмбх | Схемы дозирования и лекарственные формы для направленного ингибирования tgf-b |
TW202313678A (zh) | 2017-01-20 | 2023-04-01 | 法商賽諾菲公司 | 抗TGF-β抗體及其用途 |
CN110177568A (zh) * | 2017-01-20 | 2019-08-27 | 诺华股份有限公司 | 用于治疗癌症的组合疗法 |
EA201991729A1 (ru) * | 2017-01-20 | 2019-12-30 | Санофи | Антитела к tgf-бета и их применение |
WO2018144999A1 (en) | 2017-02-06 | 2018-08-09 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
EP3577133A1 (en) | 2017-02-06 | 2019-12-11 | Orionis Biosciences NV | Targeted chimeric proteins and uses thereof |
AU2018218557B9 (en) | 2017-02-08 | 2021-06-24 | Novartis Ag | FGF21 mimetic antibodies and uses thereof |
US11078191B2 (en) * | 2017-02-10 | 2021-08-03 | Novartis Ag | 1-(4-amino-5-bromo-6-(1H-pyrazol-1-yl)pyrimidin-2-yl)-1H-pyrazol-4-ol and use thereof in the treatment of cancer |
CN108456251A (zh) * | 2017-02-21 | 2018-08-28 | 上海君实生物医药科技股份有限公司 | 抗pd-l1抗体及其应用 |
KR102585848B1 (ko) | 2017-02-24 | 2023-10-11 | 마크로제닉스, 인크. | Cd137 및 종양 항원에 결합할 수 있는 이중특이적 결합 분자, 및 그것의 용도 |
WO2018162944A1 (en) * | 2017-03-04 | 2018-09-13 | Shenzhen Runshin Bioscience | Recombinant antibodies to programmed death 1 (pd-1) and uses therefor |
WO2018163051A1 (en) | 2017-03-06 | 2018-09-13 | Novartis Ag | Methods of treatment of cancer with reduced ubb expression |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
US20200102618A1 (en) * | 2017-03-17 | 2020-04-02 | Nantomics, Llc | LIQUID BIOPSY FOR cfRNA |
US20200108066A1 (en) * | 2017-03-30 | 2020-04-09 | Shorn Goel | Methods for modulating regulatory t cells and immune responses using cdk4/6 inhibitors |
US20190048055A1 (en) * | 2017-03-31 | 2019-02-14 | Altor Bioscience Corporation | Alt-803 in combination with anti-cd38 antibody for cancer therapies |
MX2019011572A (es) | 2017-03-31 | 2019-11-18 | Boehringer Ingelheim Int | Tratamiento conjunto antineoplasico. |
WO2018185135A1 (en) | 2017-04-05 | 2018-10-11 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
JOP20190222A1 (ar) | 2017-04-11 | 2019-09-24 | Zymeworks Inc | الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3 |
CN110573624A (zh) | 2017-04-14 | 2019-12-13 | 永恒生物科技股份有限公司 | 治疗膀胱癌的方法 |
RU2665790C1 (ru) | 2017-04-17 | 2018-09-04 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело к pd-l1 |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
WO2018201090A1 (en) | 2017-04-28 | 2018-11-01 | Exicure, Inc. | Synthesis of spherical nucleic acids using lipophilic moieties |
DK3618863T3 (da) | 2017-05-01 | 2023-08-21 | Agenus Inc | Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf |
AR111760A1 (es) | 2017-05-19 | 2019-08-14 | Novartis Ag | Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral |
AU2018274216A1 (en) | 2017-05-24 | 2019-12-12 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
EP3630162A1 (en) | 2017-05-24 | 2020-04-08 | Novartis AG | Antibody-cytokine engrafted proteins and methods of use |
WO2018215937A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer |
KR20200010501A (ko) * | 2017-05-30 | 2020-01-30 | 브리스톨-마이어스 스큅 컴퍼니 | Lag-3 양성 종양의 치료 |
JOP20190279A1 (ar) | 2017-05-31 | 2019-11-28 | Novartis Ag | الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة |
CA3065929A1 (en) | 2017-06-01 | 2018-12-06 | Michael Wayne SAVILLE | Bispecific antibodies that bind cd123 and cd3 |
WO2018223004A1 (en) | 2017-06-01 | 2018-12-06 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 |
BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
WO2018226150A1 (en) * | 2017-06-05 | 2018-12-13 | Medivir Aktiebolag | Pyrazolopyrimidine as malt-1 inhibitors |
BR112019025257A2 (pt) * | 2017-06-09 | 2020-09-29 | Glaxosmithkline Intellectual Property Development Limited | método para tratar câncer, e, anticorpo anti-icos ou porção de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou porção de ligação ao antígeno do mesmo |
US11635435B2 (en) | 2017-06-13 | 2023-04-25 | Oncotracker, Inc. | Diagnostic, prognostic, and monitoring methods for solid tumor cancers |
WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
WO2018235056A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER |
KR20200019865A (ko) | 2017-06-22 | 2020-02-25 | 노파르티스 아게 | 암 치료에 사용하기 위한 il-1베타 결합 항체 |
US20200172628A1 (en) | 2017-06-22 | 2020-06-04 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
EA202090104A1 (ru) | 2017-06-22 | 2020-04-09 | Новартис Аг | Молекулы антител к cd73 и пути их применения |
AU2018292618A1 (en) | 2017-06-27 | 2019-12-19 | Novartis Ag | Dosage regimens for anti-TIM-3 antibodies and uses thereof |
AR112603A1 (es) * | 2017-07-10 | 2019-11-20 | Lilly Co Eli | Anticuerpos biespecíficos inhibidores de punto de control |
AU2018314159A1 (en) | 2017-07-13 | 2020-01-30 | Northwestern University | General and direct method for preparing oligonucleotide-functionalized metal-organic framework nanoparticles |
CN111163798A (zh) | 2017-07-20 | 2020-05-15 | 诺华股份有限公司 | 用于抗lag-3抗体的给药方案及其用途 |
TW201912173A (zh) | 2017-08-07 | 2019-04-01 | 美商安進公司 | 三陰性乳癌或結腸直腸癌伴隨肝轉移之治療 |
WO2019032663A1 (en) * | 2017-08-09 | 2019-02-14 | Orionis Biosciences Inc. | PD-1 AND PD-L1 BINDING AGENTS |
CA3073953A1 (en) | 2017-08-31 | 2019-03-07 | Io Therapeutics, Inc. | Rar selective agonists in combination with immune modulators for cancer immunotherapy |
WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
US11760791B2 (en) * | 2017-09-13 | 2023-09-19 | Radimmune Therapeutics, Inc. | Melanin antibodies and uses thereof |
US20200239559A1 (en) | 2017-09-29 | 2020-07-30 | Boehringer Ingelheim International Gmbh | Anti igf, anti pd-1, anti-cancer combination therapy |
EA039662B1 (ru) * | 2017-10-03 | 2022-02-24 | Закрытое Акционерное Общество "Биокад" | Антитела, специфичные к cd47 и pd-l1 |
WO2019081983A1 (en) | 2017-10-25 | 2019-05-02 | Novartis Ag | CD32B TARGETING ANTIBODIES AND METHODS OF USE |
AU2018358138C1 (en) * | 2017-11-02 | 2022-12-08 | Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Bispecific antibodies and methods of making and using thereof |
CN111213059B (zh) | 2017-11-06 | 2024-01-09 | 豪夫迈·罗氏有限公司 | 用于癌症的诊断和治疗方法 |
MX2020005651A (es) | 2017-11-30 | 2020-10-28 | Novartis Ag | Receptor de antigeno quimerico dirigido a bcma y usos del mismo. |
GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
US11629189B2 (en) | 2017-12-19 | 2023-04-18 | Kymab Limited | Bispecific antibody for ICOS and PD-L1 |
WO2019129054A1 (zh) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | 三链抗体、其制备方法及其用途 |
WO2019129136A1 (zh) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | 抗pd-l1抗体及其用途 |
CN109970857B (zh) * | 2017-12-27 | 2022-09-30 | 信达生物制药(苏州)有限公司 | 抗pd-l1抗体及其用途 |
CN109970856B (zh) | 2017-12-27 | 2022-08-23 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
CN111699198B (zh) | 2017-12-28 | 2023-09-05 | 南京传奇生物科技有限公司 | 针对tigit的单域抗体和其变体 |
US20200368268A1 (en) | 2018-01-08 | 2020-11-26 | Novartis Ag | Immune-enhancing rnas for combination with chimeric antigen receptor therapy |
WO2019139388A1 (ko) * | 2018-01-10 | 2019-07-18 | 보령제약 주식회사 | Pi3 키나아제 억제제 및 면역관문 억제제를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
US20210177781A9 (en) | 2018-01-12 | 2021-06-17 | KDAc Therapeutics, Inc. | Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer |
US11713353B2 (en) | 2018-01-15 | 2023-08-01 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against PD-1 |
US11078283B2 (en) | 2018-01-17 | 2021-08-03 | Apexigen, Inc. | Anti-PD-L1 antibodies and methods of use |
US11655295B2 (en) | 2018-01-18 | 2023-05-23 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Anti-LAG-3 antibody and use thereof |
CA3088467A1 (en) * | 2018-01-23 | 2019-08-01 | Biocartis Nv | Biomarker panel and methods for detecting microsatellite instability in cancers |
AU2019215031A1 (en) | 2018-01-31 | 2020-08-20 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
EP3749295A4 (en) | 2018-02-05 | 2022-04-27 | Orionis Biosciences, Inc. | FIBROBLAST BINDING AGENTS AND USES THEREOF |
EP4317972A3 (en) | 2018-02-06 | 2024-03-13 | The General Hospital Corporation | Repeat rna as biomarkers of tumor immune response |
WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
WO2019166650A1 (en) * | 2018-03-02 | 2019-09-06 | Cdr-Life Ag | Trispecific antigen binding proteins |
WO2019179421A1 (en) * | 2018-03-19 | 2019-09-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific pd-1/ctla-4 antibody molecules |
CA3094405A1 (en) * | 2018-03-20 | 2019-09-26 | Immunovaccine Technologies Inc. | Methods and compositions for targeted delivery of active agents and immunomodulatory agents to lymph nodes |
AU2019241345A1 (en) * | 2018-03-29 | 2020-10-15 | Adagene Inc. | Anti-PD-L1 antibodies and use thereof |
US11874276B2 (en) | 2018-04-05 | 2024-01-16 | Dana-Farber Cancer Institute, Inc. | STING levels as a biomarker for cancer immunotherapy |
US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
CA3097625A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof |
WO2019204665A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
CN112166119A (zh) * | 2018-05-18 | 2021-01-01 | 陈扎克伯格生物中心公司 | 从人中分离过敏原特异性抗体的方法及其用途 |
TW202015726A (zh) | 2018-05-30 | 2020-05-01 | 瑞士商諾華公司 | Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法 |
US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
US11932681B2 (en) | 2018-05-31 | 2024-03-19 | Novartis Ag | Hepatitis B antibodies |
CA3098420A1 (en) | 2018-06-01 | 2019-12-05 | Novartis Ag | Binding molecules against bcma and uses thereof |
AU2019276656A1 (en) | 2018-06-01 | 2021-01-07 | Novartis Ag | Dosing of a bispecific antibody that bind CD123 and CD3 |
IL311536A (en) * | 2018-06-04 | 2024-05-01 | Tufts College | Binder-drug conjugates activated in the microenvironment and their related uses |
US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
MX2020013977A (es) * | 2018-06-22 | 2021-06-15 | Kite Pharma Inc | Proteínas quiméricas transmembrana y usos de las mismas. |
CA3103017A1 (en) | 2018-06-23 | 2019-12-26 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
FI3820573T3 (fi) | 2018-07-10 | 2023-11-01 | Novartis Ag | 3-(5-hydroksi-1-oksoisoindolin-2-yyli)piperidiini-2,6-dionijohdannaisia ja niiden käyttö ikaros-perheen sinkkisormi 2 (ikzf2) -riippuvaisten sairauksien hoidossa |
US20200171146A1 (en) | 2018-07-18 | 2020-06-04 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent |
KR20210038877A (ko) | 2018-07-25 | 2021-04-08 | 노파르티스 아게 | Nlrp3 인플라마좀 억제제 |
CN112041348B (zh) | 2018-07-25 | 2023-09-22 | 天境生物科技(上海)有限公司 | 抗cd73抗pd-l1双特异性抗体 |
CN113248618B (zh) * | 2018-08-21 | 2022-03-18 | 天境生物科技(杭州)有限公司 | 抗pd-l1/抗lag3双特异性抗体及其用途 |
CN112955221A (zh) | 2018-08-27 | 2021-06-11 | 皮里斯制药有限公司 | 包含cd137/her2双特异性试剂和pd-1轴抑制剂的组合疗法及其用途 |
EP3847154A1 (en) | 2018-09-03 | 2021-07-14 | F. Hoffmann-La Roche AG | Carboxamide and sulfonamide derivatives useful as tead modulators |
CN109021107B (zh) * | 2018-09-05 | 2020-08-28 | 江苏诺迈博生物医药科技有限公司 | 一种特异性结合人pd-l1的单克隆抗体及包含其的药物和试剂盒 |
WO2020053742A2 (en) | 2018-09-10 | 2020-03-19 | Novartis Ag | Anti-hla-hbv peptide antibodies |
CN110590955B (zh) * | 2018-09-17 | 2021-05-18 | 北京盛诺基医药科技股份有限公司 | 一种双特异性抗体 |
CN110960679A (zh) * | 2018-09-28 | 2020-04-07 | 江苏康缘药业股份有限公司 | 一种抗肿瘤的药物组合物及其应用 |
CA3115096A1 (en) | 2018-10-03 | 2020-04-09 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
BR112021006783A2 (pt) | 2018-10-12 | 2021-07-13 | Xencor, Inc. | proteína de fusão fc heterodimérica de il-15/r¿ direcionada, composição de ácido nucleico, composição de vetor de expressão, célula hospedeira, e, métodos de produção da proteína de fusão fc heterodimérica de il-15/r¿ direcionada e de tratamento de um câncer. |
US20220000872A1 (en) * | 2018-10-31 | 2022-01-06 | Oncotracker, Inc. | Method of enhancing immune-based therapy |
WO2020089811A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Dc-sign antibody drug conjugates |
CN113301961A (zh) * | 2018-11-01 | 2021-08-24 | 默克专利有限公司 | 给予抗tim-3抗体的方法 |
AU2019379576A1 (en) | 2018-11-13 | 2021-06-03 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
TW202038975A (zh) * | 2018-11-13 | 2020-11-01 | 美商南塞爾公司 | 多發性骨髓瘤之組合治療 |
MX2021006379A (es) * | 2018-11-30 | 2021-10-13 | Abl Bio Inc | Anticuerpos biespecificos anti-pd-l1/anti-4-1bb y usos de los mismos. |
AU2019391097A1 (en) | 2018-12-04 | 2021-05-20 | Sumitomo Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
CN113438961A (zh) | 2018-12-20 | 2021-09-24 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白 |
CA3123511A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
EP3898674A1 (en) | 2018-12-21 | 2021-10-27 | Novartis AG | Use of il-1beta binding antibodies |
WO2020128637A1 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1 binding antibodies in the treatment of a msi-h cancer |
EP3897613A1 (en) | 2018-12-21 | 2021-10-27 | Novartis AG | Use of il-1beta binding antibodies |
CN113227137A (zh) | 2018-12-21 | 2021-08-06 | 诺华股份有限公司 | IL-1β抗体在骨髓增生异常综合征的治疗或预防中的用途 |
JP2022516505A (ja) * | 2018-12-28 | 2022-02-28 | スパークス・セラピューティクス・インコーポレイテッド | 癌および他の疾患の治療のための、クローディン18.2に特異的な結合分子、その組成物および方法 |
CA3124837A1 (en) | 2019-01-14 | 2020-07-23 | Genentech, Inc. | Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine |
AU2020212767A1 (en) * | 2019-01-25 | 2021-09-02 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Combined pharmaceutical composition for treating tumor |
WO2020167990A1 (en) | 2019-02-12 | 2020-08-20 | Tolero Pharmaceuticals, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
CA3123519A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2020165833A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
KR20220004634A (ko) | 2019-03-15 | 2022-01-11 | 볼트 바이오테라퓨틱스 인코퍼레이티드 | Her2를 표적으로 하는 면역접합체 |
US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
EP3941463A1 (en) | 2019-03-22 | 2022-01-26 | Sumitomo Dainippon Pharma Oncology, Inc. | Compositions comprising pkm2 modulators and methods of treatment using the same |
WO2020209645A1 (ko) * | 2019-04-11 | 2020-10-15 | (재) 스크립스코리아항체연구원 | 프로그램화된 세포 사멸 단백질 리간드-1 (pd-l1)에 대한 항체 및 이의 용도 |
MX2021012692A (es) | 2019-04-19 | 2021-11-12 | Genentech Inc | Anticuerpos anti-mertk y sus metodos de uso. |
TW202108616A (zh) | 2019-05-03 | 2021-03-01 | 美商建南德克公司 | 用抗pd-l1抗體治療癌症之方法 |
CN113891747A (zh) * | 2019-05-15 | 2022-01-04 | 郑州威瑞生物技术有限公司 | 诱导免疫细胞活性的组合物及使用该组合物治疗疾病的方法 |
AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
EP3972982A1 (en) | 2019-05-20 | 2022-03-30 | Massachusetts Institute of Technology | Boronic ester prodrugs and uses thereof |
JP2022534889A (ja) | 2019-05-24 | 2022-08-04 | ファイザー・インコーポレイテッド | Cdk阻害剤を使用した組合せ療法 |
CN114206926B (zh) * | 2019-06-10 | 2022-06-17 | 山东博安生物技术股份有限公司 | 抗PDL1和TGFβ的双功能融合蛋白及其用途 |
CN112168961A (zh) * | 2019-07-03 | 2021-01-05 | 正大天晴药业集团南京顺欣制药有限公司 | 治疗结直肠癌的联用药物组合物 |
KR20220028075A (ko) | 2019-07-03 | 2022-03-08 | 스미토모 다이니폰 파마 온콜로지, 인크. | 티로신 키나제 비-수용체 1 (tnk1) 억제제 및 그의 용도 |
EP3996750A4 (en) * | 2019-07-12 | 2024-01-03 | Univ Oregon Health & Science | THERAPEUTIC CONSTRUCTS FOR SIMULTANEOUS ADMINISTRATION OF MITOTIC HIBITOR AND IMMUNE CHECKPOINT INHIBITOR |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
WO2021036929A1 (en) * | 2019-08-23 | 2021-03-04 | Wuxi Biologics (Shanghai) Co., Ltd. | Humanized antibodies against pd-l1 |
WO2021041532A1 (en) | 2019-08-26 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
US20210061913A1 (en) * | 2019-08-30 | 2021-03-04 | University Of Florida Research Foundation, Incorporated | Pdl-1 inhibitors in treatment of pulmonary vascular diseases |
CN114502590A (zh) | 2019-09-18 | 2022-05-13 | 诺华股份有限公司 | Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法 |
EP4031181A2 (en) * | 2019-09-18 | 2022-07-27 | Biomarker Strategies, LLC. | Methods to improve patient response to immune checkpoint inhibitors and functional tests to predict response |
TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與entpd2抗體之組合療法 |
CN115916233A (zh) | 2019-10-03 | 2023-04-04 | Xencor股份有限公司 | 靶向IL-12异源二聚体Fc融合蛋白 |
TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
EP4048285A1 (en) | 2019-10-21 | 2022-08-31 | Novartis AG | Tim-3 inhibitors and uses thereof |
CN114786679A (zh) | 2019-10-21 | 2022-07-22 | 诺华股份有限公司 | 具有维奈托克和tim-3抑制剂的组合疗法 |
EP4051321A4 (en) * | 2019-10-30 | 2023-11-22 | Duke University | IMMUNOTHERAPY WITH COMBINATION THERAPY WITH AN IMMUNE TOXIN |
CN114728905A (zh) | 2019-11-13 | 2022-07-08 | 基因泰克公司 | 治疗性化合物及使用方法 |
US20230000864A1 (en) | 2019-11-22 | 2023-01-05 | Sumitomo Pharma Oncology, Inc. | Solid dose pharmaceutical composition |
CN112574309B (zh) * | 2019-12-05 | 2023-06-16 | 启愈生物技术(上海)有限公司 | 一种抗pd-l1纳米抗体及其用途 |
CA3164623A1 (en) | 2019-12-17 | 2021-06-24 | Pfizer Inc. | Antibodies specific for cd47, pd-l1, and uses thereof |
CN115175937A (zh) | 2019-12-20 | 2022-10-11 | 诺华股份有限公司 | 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合 |
IL294608A (en) | 2020-01-10 | 2022-09-01 | Brigham & Womens Hospital Inc | Methods and compositions for administering immunotherapy agents across the blood-brain barrier for the treatment of brain cancer |
IL293752A (en) | 2020-01-17 | 2022-08-01 | Novartis Ag | A combination containing a tim-3 inhibitor and a substance that causes hypomethylation for use in the treatment of myeloplastic syndrome or chronic myelomonocytic leukemia |
MX2022009391A (es) | 2020-01-31 | 2022-09-26 | Genentech Inc | Metodos para inducir linfocitos t especificos para neoepitopo con un antagonista de union al eje de pd-1 y una vacuna de arn. |
WO2021171264A1 (en) | 2020-02-28 | 2021-09-02 | Novartis Ag | Dosing of a bispecific antibody that binds cd123 and cd3 |
IL297640A (en) * | 2020-05-12 | 2022-12-01 | Astrazeneca Ab | Methods and combinations for cancer treatment using immune checkpoint inhibitor antibodies |
CN111537726A (zh) * | 2020-05-29 | 2020-08-14 | 武汉大学 | 高效定量检测细胞外囊泡中pd-l1水平的方法、elisa试剂盒及使用方法 |
JP2023531676A (ja) | 2020-06-23 | 2023-07-25 | ノバルティス アーゲー | 3-(1-オキソイソインドリン-2-イル)ピぺリジン-2,6-ジオン誘導体を含む投与レジメン |
JP2023532768A (ja) | 2020-07-07 | 2023-07-31 | バイオエヌテック エスエー | Hpv陽性癌の治療用rna |
US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
WO2022029573A1 (en) | 2020-08-03 | 2022-02-10 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
CN111909272B (zh) * | 2020-08-12 | 2022-09-23 | 华东理工大学 | 抗pd-l1纳米抗体及其应用 |
CN111920948B (zh) * | 2020-09-25 | 2021-02-02 | 安可瑞(山西)生物细胞有限公司 | 包含免疫细胞的药物组合物用于治疗癌症 |
TW202233671A (zh) | 2020-10-20 | 2022-09-01 | 美商建南德克公司 | Peg結合抗mertk抗體及其使用方法 |
WO2022093981A1 (en) | 2020-10-28 | 2022-05-05 | Genentech, Inc. | Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists |
IL302400A (en) | 2020-11-04 | 2023-06-01 | Genentech Inc | Subcutaneous dosing of bispecific anti-CD20/anti-CD3 antibodies |
WO2022098638A2 (en) | 2020-11-04 | 2022-05-12 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
WO2022098648A2 (en) | 2020-11-04 | 2022-05-12 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
EP4240491A1 (en) | 2020-11-06 | 2023-09-13 | Novartis AG | Cd19 binding molecules and uses thereof |
EP4243827A1 (en) | 2020-11-13 | 2023-09-20 | Genentech, Inc. | Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer |
IL303256A (en) | 2020-12-02 | 2023-07-01 | Genentech Inc | Methods and compositions for the treatment of neoadjuvant and adjuvant carcinoma of the urinary tract |
TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk﹘5抑制劑和彼之用途 |
EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
US20240141060A1 (en) | 2021-01-29 | 2024-05-02 | Novartis Ag | Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof |
JP2024511373A (ja) | 2021-03-18 | 2024-03-13 | ノバルティス アーゲー | がんのためのバイオマーカーおよびその使用 |
TW202304506A (zh) | 2021-03-25 | 2023-02-01 | 日商安斯泰來製藥公司 | 涉及抗claudin 18.2抗體的組合治療以治療癌症 |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
US20220363696A1 (en) | 2021-04-13 | 2022-11-17 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
EP4330436A1 (en) | 2021-04-30 | 2024-03-06 | Genentech, Inc. | Therapeutic and diagnostic methods and compositions for cancer |
WO2022228705A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
AR125753A1 (es) | 2021-05-04 | 2023-08-09 | Agenus Inc | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos |
WO2022243378A1 (en) | 2021-05-18 | 2022-11-24 | Kymab Limited | Uses of anti-icos antibodies |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
CN113304281A (zh) * | 2021-05-28 | 2021-08-27 | 新乡医学院 | PD-1siRNA联合氯喹在制备治疗直肠癌药物中的应用 |
CN113336850B (zh) * | 2021-06-02 | 2023-06-23 | 河南中医药大学 | 一种抗人pd-l1单克隆抗体及其应用 |
GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
EP4363449A2 (en) | 2021-07-02 | 2024-05-08 | Genentech, Inc. | Methods and compositions for treating cancer |
CN113425742A (zh) * | 2021-07-08 | 2021-09-24 | 苏州珈安华钰生物科技有限公司 | 过表达CTLA-4Ig/PD-L1的宫内膜干细胞在制备治疗肺纤维化的药物中的应用 |
CN115607678A (zh) * | 2021-07-13 | 2023-01-17 | 杭州阿诺生物医药科技有限公司 | 用于治疗癌症的组合疗法 |
KR20240046323A (ko) | 2021-07-13 | 2024-04-08 | 비온테크 에스이 | 암에 대한 병용 요법에 있어서 cd40 및 cd137에 대한 다중특이 결합제 |
WO2023010094A2 (en) | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Methods and compositions for treating cancer |
CA3224180A1 (en) | 2021-07-28 | 2023-02-02 | F. Hoffmann-La Roche Ag | Methods and compositions for treating cancer |
TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗tigit抗體、抗cd38抗體及pd—1軸結合拮抗劑治療血液癌症的方法 |
WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
WO2023057882A1 (en) | 2021-10-05 | 2023-04-13 | Pfizer Inc. | Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
WO2023080900A1 (en) | 2021-11-05 | 2023-05-11 | Genentech, Inc. | Methods and compositions for classifying and treating kidney cancer |
WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
TW202332429A (zh) | 2021-11-24 | 2023-08-16 | 美商建南德克公司 | 治療性化合物及其使用方法 |
US20230203062A1 (en) | 2021-11-24 | 2023-06-29 | Genentech, Inc. | Therapeutic compounds and methods of use |
WO2023137161A1 (en) | 2022-01-14 | 2023-07-20 | Amgen Inc. | Triple blockade of tigit, cd112r, and pd-l1 |
WO2023174210A1 (en) | 2022-03-14 | 2023-09-21 | Laekna Limited | Combination treatment for cancer |
WO2023191816A1 (en) | 2022-04-01 | 2023-10-05 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023194656A1 (en) * | 2022-04-08 | 2023-10-12 | Tilt Biotherapeutics Oy | Monoclonal pd-l1 antibodies |
WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
WO2023219613A1 (en) | 2022-05-11 | 2023-11-16 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023220703A1 (en) | 2022-05-12 | 2023-11-16 | Genentech, Inc. | Methods and compositions comprising a shp2 inhibitor and a pd-l1 binding antagonist |
WO2023222854A1 (en) | 2022-05-18 | 2023-11-23 | Kymab Limited | Uses of anti-icos antibodies |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
CN114736880B (zh) * | 2022-06-09 | 2022-09-27 | 中国农业科学院北京畜牧兽医研究所 | 酸稳定性提高葡萄糖氧化酶GoxM10的突变体D497N及其衍生突变体和应用 |
WO2024015803A2 (en) | 2022-07-11 | 2024-01-18 | Autonomous Therapeutics, Inc. | Encrypted rna and methods of its use |
WO2024015897A1 (en) | 2022-07-13 | 2024-01-18 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024020432A1 (en) | 2022-07-19 | 2024-01-25 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
US20240067627A1 (en) | 2022-08-03 | 2024-02-29 | Novartis Ag | Nlrp3 inflammasome inhibitors |
WO2024036271A1 (en) * | 2022-08-12 | 2024-02-15 | The Johns Hopkins University | Anti-pd-l1 multiparatopic antibody constructs and uses thereof |
WO2024049949A1 (en) | 2022-09-01 | 2024-03-07 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
WO2024077166A1 (en) | 2022-10-05 | 2024-04-11 | Genentech, Inc. | Methods and compositions for classifying and treating lung cancer |
WO2024077095A1 (en) | 2022-10-05 | 2024-04-11 | Genentech, Inc. | Methods and compositions for classifying and treating bladder cancer |
WO2024091991A1 (en) | 2022-10-25 | 2024-05-02 | Genentech, Inc. | Therapeutic and diagnostic methods for multiple myeloma |
Family Cites Families (412)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4433059A (en) | 1981-09-08 | 1984-02-21 | Ortho Diagnostic Systems Inc. | Double antibody conjugate |
US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
EP0090505B1 (en) | 1982-03-03 | 1990-08-08 | Genentech, Inc. | Human antithrombin iii, dna sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin iii, and pharmaceutical compositions comprising it |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
US4978672A (en) | 1986-03-07 | 1990-12-18 | Ciba-Geigy Corporation | Alpha-heterocyclc substituted tolunitriles |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
EP0296122B1 (en) | 1987-06-17 | 1993-09-29 | Sandoz Ag | Cyclosporins and their use as pharmaceuticals |
JPH021556A (ja) | 1988-06-09 | 1990-01-05 | Snow Brand Milk Prod Co Ltd | ハイブリッド抗体及びその作製方法 |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
JP3771253B2 (ja) | 1988-09-02 | 2006-04-26 | ダイアックス コープ. | 新規な結合タンパク質の生成と選択 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
WO1991003493A1 (en) | 1989-08-29 | 1991-03-21 | The University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
DK0710719T3 (da) | 1990-01-12 | 2007-07-09 | Amgen Fremont Inc | Frembringelse af xenogene antistoffer |
US5273743A (en) | 1990-03-09 | 1993-12-28 | Hybritech Incorporated | Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9012995D0 (en) | 1990-06-11 | 1990-08-01 | Celltech Ltd | Multivalent antigen-binding proteins |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
US5612205A (en) | 1990-08-29 | 1997-03-18 | Genpharm International, Incorporated | Homologous recombination in mammalian cells |
US5219548A (en) | 1990-10-01 | 1993-06-15 | Board Of Regents, The University Of Texas System | High affinity halogenated-tamoxifen derivatives and uses thereof |
US6096874A (en) | 1990-10-01 | 2000-08-01 | Board Of Regents, The University Of Texas System | High affinity tamoxifen derivatives |
WO1992006068A1 (en) | 1990-10-01 | 1992-04-16 | Board Of Regents, The University Of Texas System | High affinity tamoxifen derivatives and uses thereof |
DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
CA2105300C (en) | 1991-03-01 | 2008-12-23 | Robert C. Ladner | Process for the development of binding mini-proteins |
US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
US5399338A (en) | 1991-05-01 | 1995-03-21 | University Of New Mexico | Enhancement of abnormal tissue uptake of antibodies, tumor-specific agents or conjugates thereof for diagnostic imaging or therapy |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
US6511663B1 (en) | 1991-06-11 | 2003-01-28 | Celltech R&D Limited | Tri- and tetra-valent monospecific antigen-binding proteins |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
ATE151113T1 (de) | 1992-01-23 | 1997-04-15 | Merck Patent Gmbh | Fusionsproteine von monomeren und dimeren von antikörperfragmenten |
EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
WO1993023537A1 (en) | 1992-05-08 | 1993-11-25 | Creative Biomolecules | Chimeric multivalent protein analogues and methods of use thereof |
PT1498427E (pt) | 1992-08-21 | 2010-03-22 | Univ Bruxelles | Imunoglobulinas desprovidas de cadeias leves |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
DE69334287D1 (de) | 1992-09-25 | 2009-07-09 | Avipep Pty Ltd | Zielmoleküle-bindende Polypeptide bestehend aus einer IG-artigen VL Domäne die an eine IG-artige VH Domäne gebunden ist |
GB9221657D0 (en) | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant bispecific antibodies |
DK0666868T4 (da) | 1992-10-28 | 2006-09-18 | Genentech Inc | Anvendelse af anti-VEGF-antistoffer til behandling af cancer |
US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
GB9323648D0 (en) | 1992-11-23 | 1994-01-05 | Zeneca Ltd | Proteins |
WO1994013804A1 (en) | 1992-12-04 | 1994-06-23 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
US6476198B1 (en) | 1993-07-13 | 2002-11-05 | The Scripps Research Institute | Multispecific and multivalent antigen-binding polypeptide molecules |
US5635602A (en) | 1993-08-13 | 1997-06-03 | The Regents Of The University Of California | Design and synthesis of bispecific DNA-antibody conjugates |
WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
JP3659261B2 (ja) | 1994-10-20 | 2005-06-15 | モルフォシス・アクチェンゲゼルシャフト | 組換体タンパク質の多機能性複合体への標的化ヘテロ結合 |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
WO1996037621A2 (en) | 1995-05-23 | 1996-11-28 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Multimeric proteins |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
AU6873396A (en) | 1995-10-16 | 1997-05-07 | Unilever N.V. | A bifunctional or bivalent antibody fragment analogue |
US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
ES2225961T3 (es) | 1996-04-04 | 2005-03-16 | Unilever N.V. | Proteina de union a antigeno multivalente y multiespecifica. |
MY129541A (en) | 1996-06-25 | 2007-04-30 | Novartis Ag | Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
JP4440344B2 (ja) | 1996-08-16 | 2010-03-24 | シェーリング コーポレイション | 哺乳動物細胞表面抗原;関連試薬 |
ES2236634T3 (es) | 1997-04-07 | 2005-07-16 | Genentech, Inc. | Anticuerpos anti-vegf. |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
PT973804E (pt) | 1997-04-07 | 2007-03-30 | Genentech Inc | Anticorpos anti-vegf |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
CA2288994C (en) | 1997-04-30 | 2011-07-05 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
US20030207346A1 (en) | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
ATE282092T1 (de) | 1997-06-11 | 2004-11-15 | Borean Pharma As | Trimerisierendes modul |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
AU1102399A (en) | 1997-10-21 | 1999-05-10 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2 |
US6689607B2 (en) | 1997-10-21 | 2004-02-10 | Human Genome Sciences, Inc. | Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
DK1027439T3 (da) | 1997-10-27 | 2010-05-10 | Bac Ip Bv | Multivalente antigenbindende proteiner |
DK1049787T3 (da) | 1998-01-23 | 2005-04-04 | Vlaams Interuniv Inst Biotech | Antistofderivater med flere anvendelsesmuligheder |
WO1999040196A1 (en) | 1998-02-09 | 1999-08-12 | Genentech, Inc. | Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same |
HUP9900956A2 (hu) | 1998-04-09 | 2002-04-29 | Aventis Pharma Deutschland Gmbh. | Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk |
DE69925909T2 (de) | 1998-04-15 | 2006-05-11 | Brigham & Women's Hospital, Inc., Boston | T-zell inhibierende rezeptorzusammensetzungen sowie deren verwendung |
DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
DE69911793T2 (de) | 1998-07-28 | 2004-08-12 | Micromet Ag | Heterominikörper |
US6333396B1 (en) | 1998-10-20 | 2001-12-25 | Enzon, Inc. | Method for targeted delivery of nucleic acids |
US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
US7534866B2 (en) | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
JP2003504343A (ja) | 1999-07-12 | 2003-02-04 | ジェネンテック・インコーポレーテッド | 腫瘍壊死因子リガンド/レセプター相同体による血管形成及び心血管形成の促進と抑制 |
ATE353365T1 (de) | 1999-08-23 | 2007-02-15 | Dana Farber Cancer Inst Inc | Neue b7-4 moleküle und deren verwendungen |
CA2392477A1 (en) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
SI2857516T1 (sl) | 2000-04-11 | 2017-09-29 | Genentech, Inc. | Multivalentna protitelesa in njihove uporabe |
US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
AU2001264946A1 (en) | 2000-05-24 | 2001-12-03 | Imclone Systems Incorporated | Bispecific immunoglobulin-like antigen binding proteins and method of production |
CA2412377A1 (en) | 2000-06-06 | 2001-12-13 | Bristol-Myers Squibb Company | B7-related nucleic acids and polypeptides and their uses for immunomodulation |
US20020164600A1 (en) | 2000-06-28 | 2002-11-07 | Gordon Freeman | PD-L2 molecules: novel PD-1 ligands and uses therefor |
EP1294904A1 (en) | 2000-06-30 | 2003-03-26 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Heterodimeric fusion proteins |
US20020076406A1 (en) | 2000-07-25 | 2002-06-20 | Leung Shui-On | Multivalent target binding protein |
GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
US20020107363A1 (en) | 2000-09-20 | 2002-08-08 | Amgen, Inc. | B7-Like molecules and uses thereof |
CN1308447C (zh) | 2000-10-20 | 2007-04-04 | 中外制药株式会社 | 低分子化的激动剂抗体 |
WO2002035232A2 (en) | 2000-10-27 | 2002-05-02 | Mount Sinai Hospital | Method for detecting ovarian cancer based on human kallikrein 6 (hk6) |
WO2002047537A2 (en) | 2000-12-11 | 2002-06-20 | Regents Of The University Of Michigan | Compositions and methods for in situ and in vivo imaging of cells and tissues |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US20020122806A1 (en) | 2001-03-05 | 2002-09-05 | Chinnaiyan Arul M. | Compositions and methods for in situ and in vivo imaging of cells and tissues |
WO2002072635A2 (en) | 2001-03-13 | 2002-09-19 | University College London | Specific binding members |
AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
AU2002258941A1 (en) | 2001-04-20 | 2002-11-05 | Mayo Foundation For Medical Education And Research | Methods of enhancing cell responsiveness |
ATE477280T1 (de) | 2001-06-28 | 2010-08-15 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
EP1429783A4 (en) | 2001-09-04 | 2006-08-09 | Univ Texas Tech | MULTIMODAL IMAGING CHELATES FOR MULTIPLE USES |
EP1293514B1 (en) | 2001-09-14 | 2006-11-29 | Affimed Therapeutics AG | Multimeric single chain tandem Fv-antibodies |
WO2003034068A1 (en) | 2001-10-16 | 2003-04-24 | Mount Sinai Hospital | Localization of disorders associated with kallikreins |
KR20090087139A (ko) | 2001-10-30 | 2009-08-14 | 노파르티스 아게 | Flt3 수용체 티로신 키나아제 활성의 억제제로서의 스타우로스포린 유도체 |
CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
US20030211078A1 (en) | 2001-12-07 | 2003-11-13 | Heavner George A. | Pseudo-antibody constructs |
EP1467759A4 (en) | 2002-01-30 | 2006-05-31 | Brigham & Womens Hospital | COMPOSITIONS AND METHODS ASSOCIATED WITH TIM-3, TH1-SPECIFIC CELL SURFACE MOLECULE |
EA011488B1 (ru) | 2002-02-01 | 2009-04-28 | Ариад Джин Терапьютикс, Инк. | Фосфорсодержащие соединения и их получение |
JP2006502091A (ja) | 2002-03-01 | 2006-01-19 | イミューノメディクス、インコーポレイテッド | クリアランス速度を高めるための二重特異性抗体点変異 |
KR100984613B1 (ko) | 2002-03-13 | 2010-09-30 | 어레이 바이오파마 인크. | Mek 억제제로서의 n3 알킬화 벤즈이미다졸 유도체 |
AU2003227504A1 (en) | 2002-04-15 | 2003-10-27 | Chugai Seiyaku Kabushiki Kaisha | METHOD OF CONSTRUCTING scDb LIBRARY |
US7495090B2 (en) | 2002-05-23 | 2009-02-24 | The Regents Of The University Of California | Nucleic acids encoding chimeric CD154 polypeptides |
ATE481985T1 (de) | 2002-07-03 | 2010-10-15 | Ono Pharmaceutical Co | Immunpotenzierende zusammensetzungen |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
US7052694B2 (en) | 2002-07-16 | 2006-05-30 | Mayo Foundation For Medical Education And Research | Dendritic cell potentiation |
US8188116B2 (en) | 2002-09-04 | 2012-05-29 | Vanderbilt University | Agents for therapy efficacy monitoring and deep tissue imaging |
US7754884B2 (en) | 2005-01-03 | 2010-07-13 | Vanderbilt University | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging |
US20040047858A1 (en) | 2002-09-11 | 2004-03-11 | Blumberg Richard S. | Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof |
ATE466885T1 (de) | 2002-11-15 | 2010-05-15 | Novartis Vaccines & Diagnostic | Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust |
US7449300B2 (en) | 2002-11-21 | 2008-11-11 | Mayo Foundation For Medical Education And Research | Detection of antibodies specific for B7-H1 in subjects with diseases or pathological conditions mediated by activated T cells |
CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
AU2003300184B8 (en) | 2002-12-30 | 2009-12-03 | 3M Innovative Properties Company | Immunostimulatory combinations |
CN1771235B (zh) | 2003-02-11 | 2010-04-28 | 弗奈利斯(剑桥)有限公司 | 异噁唑化合物 |
EP1897548B2 (en) | 2003-02-28 | 2024-05-22 | The Johns Hopkins University | T cell regulation |
GB0305702D0 (en) | 2003-03-12 | 2003-04-16 | Univ Birmingham | Bispecific antibodies |
WO2004094613A2 (en) | 2003-04-22 | 2004-11-04 | Ibc Pharmaceuticals | Polyvalent protein complex |
WO2004107618A2 (en) | 2003-05-23 | 2004-12-09 | Wyeth | Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof |
KR20170073698A (ko) | 2003-05-30 | 2017-06-28 | 제넨테크, 인크. | 항-vegf 항체를 사용한 치료 |
EP1641826A2 (en) | 2003-06-27 | 2006-04-05 | Biogen Idec MA Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
US20050100543A1 (en) | 2003-07-01 | 2005-05-12 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
EP1660126A1 (en) | 2003-07-11 | 2006-05-31 | Schering Corporation | Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer |
US7696322B2 (en) | 2003-07-28 | 2010-04-13 | Catalent Pharma Solutions, Inc. | Fusion antibodies |
GB0317815D0 (en) | 2003-07-30 | 2003-09-03 | Amersham Health As | Imaging agents |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
FR2859725B1 (fr) | 2003-09-16 | 2006-03-10 | Neovacs | Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine |
CA2542046A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Fused protein composition |
EP1682103A1 (en) | 2003-10-27 | 2006-07-26 | Novartis AG | Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation |
JP2007511503A (ja) | 2003-11-17 | 2007-05-10 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 医療画像化技術用の造影剤及びその使用 |
WO2005055808A2 (en) | 2003-12-02 | 2005-06-23 | Genzyme Corporation | Compositions and methods to diagnose and treat lung cancer |
AU2004308439A1 (en) | 2003-12-22 | 2005-07-14 | Centocor, Inc. | Methods for generating multimeric molecules |
GB0329825D0 (en) | 2003-12-23 | 2004-01-28 | Celltech R&D Ltd | Biological products |
US20050266425A1 (en) | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
HUE039803T2 (hu) | 2004-01-07 | 2019-02-28 | Novartis Vaccines & Diagnostics Inc | M-CSF-specifikus monoklonális ellenanyag és alkalmazásai |
AU2005207946A1 (en) | 2004-01-23 | 2005-08-11 | Amgen Inc. | Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer |
US8383575B2 (en) | 2004-01-30 | 2013-02-26 | Paul Scherrer Institut | (DI)barnase-barstar complexes |
US7333845B2 (en) | 2004-02-06 | 2008-02-19 | Wake Forest University Health Sciences | Non-invasive imaging for determination of global tissue characteristics |
US7747308B2 (en) | 2004-02-06 | 2010-06-29 | Wake Forest University Health Sciences | Non-invasive systems and methods for the determination of cardiac injury using a characterizing portion of a voxel histogram |
GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
RS55551B1 (sr) | 2004-05-13 | 2017-05-31 | Icos Corp | Hinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta |
EP1765402A2 (en) | 2004-06-04 | 2007-03-28 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
PL1761528T3 (pl) | 2004-06-11 | 2008-05-30 | Japan Tobacco Inc | Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-D]pirymidyny i związki pokrewne do leczenia raka |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
ES2427147T3 (es) | 2004-06-30 | 2013-10-29 | Mayo Foundation For Medical Education And Research | Anticuerpo sHlgM12 útil para tratar esclerosis múltiple |
JP2008512352A (ja) | 2004-07-17 | 2008-04-24 | イムクローン システムズ インコーポレイティド | 新規な四価の二重特異性抗体 |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
JP2008511337A (ja) | 2004-09-02 | 2008-04-17 | ジェネンテック・インコーポレーテッド | ヘテロ多量体分子 |
MX2007004176A (es) | 2004-10-06 | 2007-06-15 | Mayo Foundation | B7-h1 y metodos de diagnosis, prognosis, y tratamiento de cancer. |
CA2597098C (en) | 2005-02-08 | 2016-08-02 | Steven R. Ledbetter | Antibodies to tgfbeta |
DK1861713T3 (da) | 2005-03-21 | 2010-01-11 | Ge Healthcare Ltd | Fremgangsmåde til udvælgelse af PET-sporstoffer til tidlig kontrol af kræftbehandling |
ES2657443T3 (es) | 2005-03-25 | 2018-03-05 | Gitr, Inc. | Anticuerpos anti-GITR y usos de los mismos |
WO2006106905A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 会合制御によるポリペプチド製造方法 |
CA2604032C (en) | 2005-04-06 | 2017-08-22 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
ES2707152T3 (es) | 2005-04-15 | 2019-04-02 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
PT2650020T (pt) | 2005-05-06 | 2016-12-12 | Providence Health & Services - Oregon | Proteína de fusão de imunoglobulina ox-40 trimérica e métodos do campo de utilização |
SI2439273T1 (sl) | 2005-05-09 | 2019-05-31 | Ono Pharmaceutical Co., Ltd. | Človeška monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka z uporabo protiteles proti PD-1 samostojno ali v kombinaciji z ostalimi imunoterapevtiki |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
US20060263367A1 (en) | 2005-05-23 | 2006-11-23 | Fey Georg H | Bispecific antibody devoid of Fc region and method of treatment using same |
CN104436190A (zh) * | 2005-06-08 | 2015-03-25 | 达纳-法伯癌症研究院公司 | 通过抑制程序性细胞死亡1(pd-1)途经治疗持续性感染和癌症的方法及组合物 |
CN101248089A (zh) | 2005-07-01 | 2008-08-20 | 米德列斯公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
JP4557003B2 (ja) | 2005-07-01 | 2010-10-06 | 株式会社村田製作所 | 多層セラミック基板およびその製造方法ならびに多層セラミック基板作製用複合グリーンシート |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
DE602005018477D1 (de) | 2005-08-26 | 2010-02-04 | Pls Design Gmbh | Bivalente IgY Antikörperkonstrukte für diagnostische und therapeutische Anwendungen |
PE20070427A1 (es) | 2005-08-30 | 2007-04-21 | Novartis Ag | Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas |
WO2007044887A2 (en) | 2005-10-11 | 2007-04-19 | Transtarget, Inc. | Method for producing a population of homogenous tetravalent bispecific antibodies |
EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
EP1962961B1 (en) | 2005-11-29 | 2013-01-09 | The University Of Sydney | Demibodies: dimerisation-activated therapeutic agents |
MY147379A (en) | 2005-12-02 | 2012-11-30 | Sinai School Medicine | Chimeric viruses presenting non-native surface proteins and uses thereof |
ES2612196T3 (es) | 2005-12-13 | 2017-05-12 | Incyte Holdings Corporation | Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus |
SI2347775T1 (sl) | 2005-12-13 | 2020-10-30 | President And Fellows Of Harvard College | Ogrodja za celično transplantacijo |
SI2481753T1 (en) | 2005-12-13 | 2018-06-29 | Eli Lilly And Company | Anti-IL-17 antibodies |
EP1981969A4 (en) | 2006-01-19 | 2009-06-03 | Genzyme Corp | ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
WO2007095338A2 (en) | 2006-02-15 | 2007-08-23 | Imclone Systems Incorporated | Functional antibodies |
BRPI0709598A8 (pt) | 2006-03-17 | 2019-01-08 | Biogen Idec Inc | composições de polipeptídeos estabilizados |
WO2007112362A2 (en) | 2006-03-24 | 2007-10-04 | The Regents Of The University Of California | Construction of a multivalent scfv through alkyne-azide 1,3-dipolar cycloaddition |
ES2395969T3 (es) | 2006-03-24 | 2013-02-18 | Merck Patent Gmbh | Dominios de proteínas heterodiméricas genéticamente modificados |
DK2009101T3 (en) | 2006-03-31 | 2018-01-15 | Chugai Pharmaceutical Co Ltd | Antibody modification method for purification of a bispecific antibody |
WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
EP2010528B1 (en) | 2006-04-19 | 2017-10-04 | Novartis AG | 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling |
UA93548C2 (uk) | 2006-05-05 | 2011-02-25 | Айерем Елелсі | Сполуки та композиції як модулятори хеджхогівського сигнального шляху |
WO2007137760A2 (en) | 2006-05-25 | 2007-12-06 | Bayer Schering Pharma Aktiengesellschaft | Dimeric molecular complexes |
US20070274985A1 (en) | 2006-05-26 | 2007-11-29 | Stefan Dubel | Antibody |
MX2008015524A (es) | 2006-06-12 | 2009-01-13 | Trubion Pharmaceuticals Inc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
PE20110218A1 (es) | 2006-08-02 | 2011-04-01 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
US8759297B2 (en) | 2006-08-18 | 2014-06-24 | Armagen Technologies, Inc. | Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns |
ES2444065T3 (es) | 2006-08-18 | 2014-02-24 | Novartis Ag | Anticuerpo específico para PRLR y usos del mismo |
KR101428116B1 (ko) | 2006-08-21 | 2014-08-07 | 제넨테크, 인크. | 아자-벤조푸라닐 화합물 및 사용 방법 |
US20100258138A1 (en) | 2006-08-22 | 2010-10-14 | Jens Sorensen | Radiolabeled 1-acetate pet imaging for radiotherapy in head and neck cancer |
WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
US9382327B2 (en) * | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
GB0620894D0 (en) | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
SG176476A1 (en) | 2006-11-02 | 2011-12-29 | Daniel J Capon | Hybrid immunoglobulins with moving parts |
US7894649B2 (en) | 2006-11-02 | 2011-02-22 | Accuray Incorporated | Target tracking using direct target registration |
HUE026659T2 (en) | 2006-11-22 | 2016-07-28 | Incyte Holdings Corp | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
US20100324130A1 (en) | 2006-12-05 | 2010-12-23 | Bornhop Darryl J | Daa peripheral benzodiazepine receptor ligand for cancer imaging and treatment |
US20080318886A1 (en) | 2006-12-05 | 2008-12-25 | Prussak Charles E | Methods of Increasing Cancer Sensitivity to Chemotherapeutic Agents Using Chimeric ISF35 |
JP5208123B2 (ja) | 2006-12-08 | 2013-06-12 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
WO2008071447A2 (en) | 2006-12-15 | 2008-06-19 | Ablynx N.V. | Amino acid sequences that modulate the interaction between cells of the immune system |
US20080146914A1 (en) | 2006-12-19 | 2008-06-19 | General Electric Company | System, method and apparatus for cancer imaging |
WO2008140621A2 (en) | 2006-12-21 | 2008-11-20 | Mount Sinai School Of Medicine Of New York University | Transgenic oncolytic viruses and uses thereof |
NZ578650A (en) | 2006-12-27 | 2011-12-22 | Harvard College | Pd-1 and activated t-cell compositions and methods for the treatment of viral infections and tumors |
US8287471B2 (en) | 2007-02-20 | 2012-10-16 | National Health Research Institutes | Medical treatment using an ultrasound phased array |
US20100092384A1 (en) | 2007-03-19 | 2010-04-15 | The Junited States Of America As Represented By Secretary, Dept. Of Health And Human Service | Multifunctional nanoparticles and compositions and methods of use thereof |
US7848557B2 (en) | 2007-03-23 | 2010-12-07 | University Of Utah Research Foundation | Rapid multi-tracer PET imaging systems and methods |
ES2593484T3 (es) | 2007-03-29 | 2016-12-09 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
WO2008131242A1 (en) | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Single chain fc, methods of making and methods of treatment |
CA2691089A1 (en) * | 2007-06-15 | 2008-12-24 | Immurx, Inc. | Use of tlr agonists and/or type 1 interferons to alleviate toxicity of tnf-r agonist therapeutic regimens |
KR101586617B1 (ko) * | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 pd-1에 대한 항체 |
US9770535B2 (en) | 2007-06-21 | 2017-09-26 | President And Fellows Of Harvard College | Scaffolds for cell collection or elimination |
JP2010531878A (ja) | 2007-06-27 | 2010-09-30 | マリン ポリマー テクノロジーズ,インコーポレーテッド | IL‐15とIL‐15Rαとの複合体及びその使用 |
EP3124046B1 (en) | 2007-07-12 | 2019-12-25 | GITR, Inc. | Combination therapies employing gitr binding molecules |
EP2514762B1 (en) | 2007-07-13 | 2015-04-08 | The Johns Hopkins University | B7-DC variants |
WO2009012288A2 (en) | 2007-07-17 | 2009-01-22 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Trifunctional imaging agent for monoclonal antibody tumor-targeted imaging |
WO2009018386A1 (en) | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
EP2178914A2 (en) | 2007-08-15 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Monospecific and multispecific antibodies and method of use |
CA2706425A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
EP2615115A3 (en) | 2007-11-30 | 2014-01-08 | Glaxo Group Limited | Antigen-binding constructs |
RU2441004C1 (ru) | 2007-12-19 | 2012-01-27 | Дженентек, Инк. | 5-анилиноимидазопиридины и способы их применения |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
WO2009101611A1 (en) | 2008-02-11 | 2009-08-20 | Curetech Ltd. | Monoclonal antibodies for tumor treatment |
CA2715460C (en) | 2008-02-13 | 2020-02-18 | President And Fellows Of Harvard College | Continuous cell programming devices |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
JP5547099B2 (ja) | 2008-03-14 | 2014-07-09 | インテリカイン, エルエルシー | キナーゼ阻害剤および使用方法 |
AR070924A1 (es) | 2008-03-19 | 2010-05-12 | Novartis Ag | Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona |
EP2106806A1 (en) | 2008-03-31 | 2009-10-07 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Nanoparticles for targeted delivery of active agents to the lung |
SI2300455T1 (sl) | 2008-05-21 | 2017-12-29 | Incyte Holdings Corporation | Soli 2-fluoro-n-metil-4-(7-(kinolin-6-il-metil)-imidazo(1,2-b)1,2,4) triazin-2-il)benzamid in postopki v zvezi z njihovo pripravo |
JP5351254B2 (ja) | 2008-05-23 | 2013-11-27 | ノバルティス アーゲー | キノキサリン−およびキノリン−カルボキシアミド誘導体 |
UY31929A (es) | 2008-06-25 | 2010-01-05 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa |
AU2009266873A1 (en) | 2008-07-02 | 2010-01-07 | Emergent Product Development Seattle, Llc | TGF-beta antagonist multi-target binding proteins |
AU2009268611B2 (en) | 2008-07-08 | 2015-04-09 | Intellikine, Llc | Kinase inhibitors and methods of use |
RS54299B1 (en) | 2008-07-17 | 2016-02-29 | Novartis Ag | COMPOSITIONS AND METHODS OF USING THERAPY ANTIBODIES |
US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
CA2660507C (en) | 2008-08-06 | 2017-12-12 | Jie Chen | Targeted nanoparticles for cancer diagnosis and treatment |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
CN102186856B (zh) | 2008-08-22 | 2014-09-24 | 诺华股份有限公司 | 作为cdk抑制剂的吡咯并嘧啶化合物 |
JP2012510429A (ja) | 2008-08-25 | 2012-05-10 | アンプリミューン、インコーポレーテッド | Pd−1アンタゴニストおよびその使用方法 |
PE20110435A1 (es) | 2008-08-25 | 2011-07-20 | Amplimmune Inc | Composiciones antagonistas del pd-1 |
PL2344474T3 (pl) | 2008-09-02 | 2016-03-31 | Novartis Ag | Pochodne pikolinamidu jako inhibitory kinaz |
UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
WO2010030002A1 (ja) | 2008-09-12 | 2010-03-18 | 国立大学法人三重大学 | 外来性gitrリガンド発現細胞 |
SI2342226T1 (sl) * | 2008-09-26 | 2016-11-30 | Dana-Farber Cancer Institute Inc. | Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe |
EP2346508B1 (en) | 2008-09-26 | 2016-08-24 | Intellikine, LLC | Heterocyclic kinase inhibitors |
KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 항암제 |
EP2362783A2 (en) | 2008-10-31 | 2011-09-07 | Biogen Idec MA Inc. | Light targeting molecules and uses thereof |
WO2010056735A1 (en) | 2008-11-11 | 2010-05-20 | The Trustees Of The University Of Pennsylvania | Compositions and methods for inhibiting an oncogenic protein to enhance immunogenicity |
CA2744937C (en) | 2008-11-28 | 2017-02-28 | Novartis Ag | Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor |
UA109108C2 (uk) | 2008-12-09 | 2015-07-27 | Дженентек, Інк. | Антитіло до pd-l1 та його застосування для посилення функції t-клітин |
US8591881B2 (en) | 2009-02-05 | 2013-11-26 | Mount Sinai School Of Medicine | Chimeric Newcastle disease viruses and uses thereof |
ES2629337T3 (es) | 2009-02-09 | 2017-08-08 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos |
UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
WO2010102278A1 (en) | 2009-03-06 | 2010-09-10 | President And Fellows Of Harvard College | Methods and compositions for the generation and maintenance of regulatory t cells |
EP2417984B1 (en) | 2009-04-10 | 2016-03-30 | Kyowa Hakko Kirin Co., Ltd. | Method for treatment of blood tumor using anti-tim-3 antibody |
WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
RU2016134843A (ru) | 2009-04-30 | 2018-12-11 | Тел Хашомер Медикал Рисерч Инфрастракче Энд Сервисиз Лтд. | Антитела к ceacam1 и способы их использования |
US20120052010A1 (en) | 2009-04-30 | 2012-03-01 | Ge Healthcare Limited | Imaging tumor perfusion, oxidative metabolism using dynamic ace pet in patients with head and neck cancer during radiotherapy |
UA105794C2 (uk) | 2009-06-26 | 2014-06-25 | Новартіс Аг | 1,3-ДИЗАМІЩЕНІ ПОХІДНІ ІМІДАЗОЛІДИН-2-ОНУ ЯК ІНГІБІТОРИ Cyp17 |
ES2629167T3 (es) | 2009-07-20 | 2017-08-07 | Bristol-Myers Squibb Company | Combinación de anticuerpo anti-CTLA4 con etopósido para el tratamiento sinérgico de enfermedades proliferativas |
JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
EP2473531A4 (en) | 2009-09-03 | 2013-05-01 | Merck Sharp & Dohme | ANTI-GITRANT ANTIBODIES |
IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
GB0919054D0 (en) | 2009-10-30 | 2009-12-16 | Isis Innovation | Treatment of obesity |
ES2646863T3 (es) | 2009-11-24 | 2017-12-18 | Medimmune Limited | Agentes de unión específica contra B7-H1 |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
EP3112382A1 (en) | 2009-12-29 | 2017-01-04 | Emergent Product Development Seattle, LLC | Heterodimer binding proteins and uses thereof |
UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
CA2796571C (en) * | 2010-04-13 | 2019-10-29 | Celldex Therapeutics Inc. | Antibodies that bind human cd27 and uses thereof |
US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
US20110280877A1 (en) | 2010-05-11 | 2011-11-17 | Koji Tamada | Inhibition of B7-H1/CD80 interaction and uses thereof |
RU2613886C2 (ru) | 2010-06-03 | 2017-03-21 | Дженентек, Инк. | Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения |
EP2581113B1 (en) | 2010-06-11 | 2018-05-09 | Kyowa Hakko Kirin Co., Ltd. | Anti-tim-3 antibody |
JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのtim−3およびpd−1に対する二重特異性抗体 |
EP2591001B1 (en) | 2010-07-09 | 2021-11-17 | Aduro Biotech Holdings, Europe B.V. | Agonistic antibody to cd27 |
JP6057896B2 (ja) | 2010-08-20 | 2017-01-11 | ノバルティス アーゲー | 上皮細胞増殖因子受容体3(her3)に対する抗体 |
EP2609118B1 (en) | 2010-08-23 | 2017-01-18 | Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
EP2918607B1 (en) | 2010-09-21 | 2017-11-08 | Altor BioScience Corporation | Multimeric il-15 soluble fusion molecules and methods of making and using same |
ES2773858T3 (es) | 2010-10-06 | 2020-07-15 | Harvard College | Hidrogeles formadores de poros inyectables para terapias celulares basadas en materiales |
DK2699264T3 (en) | 2011-04-20 | 2018-06-25 | Medimmune Llc | ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1 |
WO2012149358A1 (en) | 2011-04-28 | 2012-11-01 | President And Fellows Of Harvard College | Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration |
US9486512B2 (en) | 2011-06-03 | 2016-11-08 | President And Fellows Of Harvard College | In situ antigen-generating cancer vaccine |
EP2714735B1 (en) | 2011-06-03 | 2021-07-21 | XOMA Technology Ltd. | Antibodies specific for tgf-beta |
CN103796680A (zh) | 2011-06-21 | 2014-05-14 | 约翰霍普金斯大学 | 用于增强针对赘生物的基于免疫的治疗的聚焦放射 |
US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
CA2843595C (en) | 2011-08-01 | 2022-10-18 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
JP2014527983A (ja) | 2011-09-19 | 2014-10-23 | ザ ジョンズ ホプキンス ユニバーシティー | 癌免疫療法 |
WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
PT2771364T (pt) | 2011-10-27 | 2019-09-10 | Genmab As | Produção de proteínas heterodiméricas |
DK2785375T3 (da) | 2011-11-28 | 2020-10-12 | Merck Patent Gmbh | Anti-pd-l1-antistoffer og anvendelser deraf |
GB201120527D0 (en) | 2011-11-29 | 2012-01-11 | Ucl Business Plc | Method |
CA2892371C (en) | 2011-12-01 | 2021-01-19 | The Brigham And Women's Hospital, Inc. | Anti-ceacam1 recombinant antibodies for cancer therapy |
CN104411331B (zh) | 2012-01-13 | 2018-08-21 | 哈佛学院董事会 | 在结构聚合装置中tlr激动剂的控制传递 |
UY34591A (es) | 2012-01-26 | 2013-09-02 | Novartis Ag | Compuestos de imidazopirrolidinona |
UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
CN106074368B (zh) | 2012-03-29 | 2019-01-22 | 先进癌症治疗有限责任公司 | Pfkfb3抑制剂和用作抗癌治疗剂的方法 |
ES2773895T3 (es) | 2012-04-16 | 2020-07-15 | Harvard College | Composiciones de sílice mesoporosa para modular las respuestas inmunitarias |
EP2838548B1 (en) | 2012-04-17 | 2023-07-19 | University of Washington through its Center for Commercialization | Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof |
AU2013261128B2 (en) | 2012-05-15 | 2015-11-12 | Novartis Ag | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
CA2870339C (en) | 2012-05-15 | 2020-06-02 | Novartis Ag | Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1 |
JP6448533B2 (ja) | 2012-05-15 | 2019-01-09 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Pd−1/pd−l1シグナル伝達を破壊することによる癌免疫療法 |
DK2861579T5 (da) | 2012-05-15 | 2022-10-24 | Novartis Ag | Benzamidderivater til at hæmme aktiviteten af ABL1, ABL2 og BCR-ABL1 |
BR112014027244A2 (pt) | 2012-05-15 | 2017-06-27 | Novartis Ag | derivados de benzamida para inibição da atividade de abl1, abl2 e bcr-abl1 |
EP3556776A1 (en) | 2012-05-31 | 2019-10-23 | F. Hoffmann-La Roche AG | Methods of treating cancer using pd-1 axis binding antagonists and vegf antagonists |
KR102410078B1 (ko) | 2012-05-31 | 2022-06-22 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
JO3300B1 (ar) | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
KR101566539B1 (ko) | 2012-06-08 | 2015-11-05 | 국립암센터 | 신규한 Th2 세포 전환용 에피토프 및 이의 용도 |
AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
CN103566377A (zh) | 2012-07-18 | 2014-02-12 | 上海博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
KR20150038066A (ko) | 2012-07-30 | 2015-04-08 | 알렉스 와 힌 영 | 종양 세포, 암세포파괴 바이러스 벡터 및 면역 체크포인트 조절인자를 갖는 암 백신 시스템 |
US10513540B2 (en) | 2012-07-31 | 2019-12-24 | The Brigham And Women's Hospital, Inc. | Modulation of the immune response |
CN111499755A (zh) | 2012-08-03 | 2020-08-07 | 丹娜法伯癌症研究院 | 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法 |
TWI472974B (zh) | 2012-09-06 | 2015-02-11 | Au Optronics Corp | 多類物體觸控點偵測方法 |
US20150250837A1 (en) | 2012-09-20 | 2015-09-10 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
CN107892719B (zh) * | 2012-10-04 | 2022-01-14 | 达纳-法伯癌症研究所公司 | 人单克隆抗-pd-l1抗体和使用方法 |
WO2014066527A2 (en) | 2012-10-24 | 2014-05-01 | Admune Therapeutics Llc | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
AU2013343425A1 (en) | 2012-11-08 | 2015-06-11 | Novartis Ag | Pharmaceutical combination comprising a B-Raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases |
EP2925365A1 (en) | 2012-11-28 | 2015-10-07 | Novartis AG | Combination therapy |
AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
EA031537B1 (ru) | 2013-02-08 | 2019-01-31 | Новартис Аг | Антитела против il-17a и их применение для лечения аутоиммунных и воспалительных нарушений |
WO2014165082A2 (en) | 2013-03-13 | 2014-10-09 | Medimmune, Llc | Antibodies and methods of detection |
US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
SG10201802982WA (en) | 2013-03-14 | 2018-06-28 | Icahn School Med Mount Sinai | Newcastle disease viruses and uses thereof |
US9434719B2 (en) | 2013-03-14 | 2016-09-06 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
US20160084839A1 (en) | 2013-04-02 | 2016-03-24 | Marisa Dolled-Filhart | Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue |
CN105188373B (zh) | 2013-05-18 | 2017-09-22 | 艾杜罗生物科技公司 | 抑制“干扰素基因刺激蛋白”依赖性信号传导的组合物和方法 |
JP6453855B2 (ja) | 2013-05-18 | 2019-01-16 | アドゥロ バイオテック,インク. | 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を活性化するための組成物及び方法 |
JP2016520643A (ja) | 2013-06-03 | 2016-07-14 | ノバルティス アーゲー | 抗pd−l1抗体とmek阻害薬および/またはbraf阻害薬の組み合わせ物 |
KR102232153B1 (ko) | 2013-08-20 | 2021-03-24 | 머크 샤프 앤드 돔 코포레이션 | Pd-1 길항제와 디나시클립의 조합을 사용한 암의 치료 |
AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
KR20240056664A (ko) | 2013-09-11 | 2024-04-30 | 메디뮨 리미티드 | 종양 치료용 항-b7-h1 항체 |
AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
EA201991715A1 (ru) | 2013-09-27 | 2020-03-31 | Дженентек, Инк. | Композиции, содержащие антитело к pdl1 |
US10202454B2 (en) | 2013-10-25 | 2019-02-12 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
HUE039306T2 (hu) | 2013-11-01 | 2018-12-28 | Novartis Ag | Kináz inhibitor aminoheteroaril-benzamidok |
WO2015081158A1 (en) | 2013-11-26 | 2015-06-04 | Bristol-Myers Squibb Company | Method of treating hiv by disrupting pd-1/pd-l1 signaling |
US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
WO2015085179A1 (en) | 2013-12-06 | 2015-06-11 | The Regents Of The University Of California | Alpha-v beta-6 integrin-binding antibody fragments |
CN106102774A (zh) | 2013-12-17 | 2016-11-09 | 豪夫迈·罗氏有限公司 | 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法 |
US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
GB201322583D0 (en) | 2013-12-19 | 2014-02-05 | Alligator Bioscience Ab | Antibodies |
WO2015095811A2 (en) | 2013-12-20 | 2015-06-25 | The Board Institute Inc. | Combination therapy with neoantigen vaccine |
EP3702785A1 (en) | 2013-12-30 | 2020-09-02 | The Scripps Research Institute | Circulating tumor cell diagnostics for lung cancer |
US10150804B2 (en) | 2014-01-03 | 2018-12-11 | British Columbia Cancer Agency Branch | Compositions and methods for imaging cancer |
KR102395498B1 (ko) | 2014-01-06 | 2022-05-09 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용 |
US20150190534A1 (en) | 2014-01-09 | 2015-07-09 | University Of Bern | Compounds for use as positron emission imaging agents |
HUE057917T2 (hu) | 2014-01-15 | 2022-06-28 | Kadmon Corp Llc | Immunmodulátor szerek |
TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
KR20220153677A (ko) | 2014-02-04 | 2022-11-18 | 인사이트 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 ido1 억제제의 조합 |
CA2937035A1 (en) | 2014-02-05 | 2015-08-13 | Cedars-Sinai Medical Center | Methods and compositions for treating cancer and infectious diseases |
WO2015119763A1 (en) | 2014-02-06 | 2015-08-13 | Immunomedics, Inc. | Al-f-18-labeled, al-f-19-labeled and ga-68-labeled gastrin-releasing peptide receptor (grpr)-antagonists for imaging of prostate cancer |
CN113549159A (zh) | 2014-02-10 | 2021-10-26 | 默克专利有限公司 | 靶向TGFβ抑制 |
CU24481B1 (es) | 2014-03-14 | 2020-03-04 | Immutep Sas | Moléculas de anticuerpo que se unen a lag-3 |
EP3149042B1 (en) | 2014-05-29 | 2019-08-28 | Spring Bioscience Corporation | Pd-l1 antibodies and uses thereof |
WO2015195163A1 (en) | 2014-06-20 | 2015-12-23 | R-Pharm Overseas, Inc. | Pd-l1 antagonist fully human antibody |
KR102130600B1 (ko) | 2014-07-03 | 2020-07-08 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
US9993551B2 (en) | 2014-09-13 | 2018-06-12 | Novartis Ag | Combination therapies of EGFR inhibitors |
KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對pd-l1之抗體分子及其用途 |
WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
CN108025051B (zh) | 2015-07-29 | 2021-12-24 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
PT3317301T (pt) | 2015-07-29 | 2021-07-09 | Novartis Ag | Terapias de associação compreendendo moléculas de anticorpo contra lag-3 |
AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
CA3007481C (en) | 2015-12-07 | 2024-01-30 | Merck Patent Gmbh | Aqueous pharmaceutical formulation comprising anti-pd-l1 antibody avelumab |
JP2019503349A (ja) | 2015-12-17 | 2019-02-07 | ノバルティス アーゲー | Pd−1に対する抗体分子およびその使用 |
US10421811B2 (en) | 2016-04-25 | 2019-09-24 | Medimmune, Llc | Compositions comprising coformulation of anti-PD-L1 and anti-CTLA-4 antibodies |
-
2015
- 2015-10-13 TW TW104133578A patent/TWI716362B/zh active
- 2015-10-13 WO PCT/US2015/055390 patent/WO2016061142A1/en active Application Filing
- 2015-10-13 MA MA040035A patent/MA40035A/fr unknown
- 2015-10-13 PE PE2017000603A patent/PE20171067A1/es unknown
- 2015-10-13 US US14/881,888 patent/US9988452B2/en active Active
- 2015-10-13 EA EA201790834A patent/EA201790834A1/ru unknown
- 2015-10-13 AU AU2015333687A patent/AU2015333687B2/en active Active
- 2015-10-13 CN CN201580067903.4A patent/CN107001478B/zh active Active
- 2015-10-13 CU CUP2017000052A patent/CU20170052A7/es unknown
- 2015-10-13 CN CN202210015917.3A patent/CN114920840A/zh active Pending
- 2015-10-13 CR CR20170143A patent/CR20170143A/es unknown
- 2015-10-13 EP EP23169814.3A patent/EP4245376A3/en active Pending
- 2015-10-13 EP EP15784907.6A patent/EP3206711B1/en active Active
- 2015-10-13 SG SG11201702401RA patent/SG11201702401RA/en unknown
- 2015-10-13 UY UY0001036351A patent/UY36351A/es not_active Application Discontinuation
- 2015-10-13 MX MX2017004810A patent/MX2017004810A/es unknown
- 2015-10-13 KR KR1020177012615A patent/KR102513870B1/ko active IP Right Grant
- 2015-10-13 BR BR112017007379A patent/BR112017007379A2/pt active Search and Examination
- 2015-10-13 ES ES15784907T patent/ES2952717T3/es active Active
- 2015-10-13 CA CA2964367A patent/CA2964367C/en active Active
- 2015-10-13 TN TN2017000129A patent/TN2017000129A1/en unknown
- 2015-10-13 JP JP2017519875A patent/JP6877339B2/ja active Active
-
2017
- 2017-04-04 IL IL251563A patent/IL251563B/en active IP Right Grant
- 2017-04-11 CL CL2017000888A patent/CL2017000888A1/es unknown
- 2017-04-11 PH PH12017500692A patent/PH12017500692A1/en unknown
- 2017-04-11 CO CONC2017/0003490A patent/CO2017003490A2/es unknown
- 2017-04-11 GT GT201700081A patent/GT201700081A/es unknown
- 2017-05-11 EC ECIEPI201729218A patent/ECSP17029218A/es unknown
-
2018
- 2018-02-20 US US15/900,153 patent/US10851165B2/en active Active
-
2020
- 2020-10-23 US US17/078,929 patent/US20210284737A1/en not_active Abandoned
-
2021
- 2021-04-27 JP JP2021074865A patent/JP2021121593A/ja active Pending
-
2023
- 2023-06-06 JP JP2023093453A patent/JP2023126761A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20170052A7 (es) | Moléculas de anticuerpo que se unen a pd-l1 | |
CU24481B1 (es) | Moléculas de anticuerpo que se unen a lag-3 | |
PH12018501206A1 (en) | Antibody molecules to pd-1 and uses thereof | |
ECSP16068976A (es) | Moléculas de anticuerpo que se unen a pd-1 y usos de las mismas | |
UY35973A (es) | Moléculas de anticuerpo que se unen a tim-3 y usos de las mismas | |
AR104081A1 (es) | Moléculas de anticuerpo que se unen a pd-l1 y sus usos |